Binding of HIV-1 gp120 to the nicotinic receptor  by Bracci, Luisa et al.
Volume 3! !. number 2, 115-l I8 FEBS 11637 
Q 1992 Federation of European Biochemical Socictics 00145793~91/55.00 
Oc1ober 1992 
Binding of HIV-l gp120 to the nicotinic receptor 
Luisa Bracci, Luisa Lozzi, Mauro Rustici and Paolo Neri 
Received 14 July 1992; revised version received 2 September 1992 
We previously described n si@icant sequence homology between HIV-I gpl20 and the functional sites rcsponsiblc for the specific bindingofsnakc 
curarc-mimetic ncurotoxins and rabies virus glycoprotcin to the nicotinic acctylcholine receptor. Hcrc we report findin@ about the existcncc of 
a mechanism of functional molecular mimicry which could enable the binding of HIV-l gp120 to nicotinic acctylcholinc receptors in muscle cells 
and neurons. 
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I. 1NTRODUCTION 
In a previous paper [l] we reported a significant ho- 
mology between the sequence, 164-174 [2], of HIV-l 
gpl20 and the putative active sites of snake curare- 
mimetic neurotoxins and rabies virus (RV) glycopro- 
tein, which specifically bind to the nicotinic ace- 
tylcholinc receptor (AChR). Curare-mimetic neurotox- 
ins from Elapid snakes bind with high affinity to AChR 
and competitively block acetylcholine-induced mem- 
branc depolarization [3]. On the other hand the rabies 
virus binds to the muscle nicotinic receptor and this 
binding is inhibited by snake neurotoxins [4]. We con- 
sider the homology of gp120 with snake ncurotoxins 
and RV glycoprotein to be of potential importance for 
HIV-1 infectivity in that it is centered around a region 
comprising highly conserved snake neurotoxin residues 
probably involved in receptor binding; moreover, in 
rabies virus glycoprotein, the same sequence corre- 
sponds to the site of rabies virus binding to AChR [5,6]. 
We proposed that nicotinic acetylcholine receptors 
can function as HIV-I receptors in muscle cells and 
neurones, by virtue of mimicry of receptor-specific a - 
tive sites of ligands by HT’V-1 gpl20. A similar mecha- 
nism is already suspected for rabies virus binding to 
muscle cells [G]. 
We found that recombinant gp I20 from HIV-l strain 
IIIB is able to inhibit the binding of the snake neuro- 
toxin, a-bungarotoxin (a-Bgt), to the nicotinic ace- 
tylcholine receptor in the human rhabdomyosarcoma 
cell line, TE671. A 14-amino acid synthetic peptide 
(HG165-178: Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys- 
Val-Gin-Lys-Glu-Tyr), reproducing the sequence 165- 
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178 of gp120, homologous to snake ncurotoxins and 
rabies virus glycopratein, is also able, once conjugated 
to keyhole limpet hemocyanin (KLH), to inhibit the 
binding of a-Bgt to TE67 I nicotinic acetylcholine recep- 
tor. Further, immunization of mice with the same 
gpl20-derived peptide gave rise to antibodies efficiently 
cross-reacting with rabies virus glycoprotein and a-Bgt. 
2. MATERIALS AND METHODS 
The human cell line, TE67 I, was obtained from the American Type 
Culture Collection. Cells were grown to cordluencc at 37°C in Dnl- 
bccco’s modified Eagle’s medium supplemented with 10% hcat-inac- 
tivated fetal calf serum. 
2.2. loditruriutr 0J a-hurtgut-orosh 
a-B@ was obtained from Sigma (St. Louis. MO, USA) and lab&d 
with “‘1 as described [7]; specific activity was 2-3 x 10” cpm/mol. 
For binding cxpcrimcnts, cells wcrc harvested mechanically with a 
rubber policeman and centrifuged at 450 x 8 for I5 min: pellets were 
resuspended in phosphate buffered saline (PBS), pH 7.5. to a density 
of IO’ cells/ml; IO” cells were incubated with 50 jtl of serial dilutions 
of HIV-I gpl20 (IIIB strain. Ncosystem Ldboratoirc. Strasbourg. 
France) for 3 h under gentle stirring, 5Oyl of [1z511~-Bgt (10’cpm) were 
then added and the cells incubated for a further 45 min. Binding was 
stopped by the addition of 1 ml ice-cold PBS containing I mdml BSA 
and samples were then centrifuged at 450 x g for I5 min at 4°C. The 
cell pellets were washed twice as above and cou~wd in a r-counter 
(Minimaxi 500. Packard Instruments Co.. Downers Grove, IL). Max- 
imum binding was obtained by replacing inhibitors with assay buffer. 
Non-specific binding was dctcrmined in the prcssencc of 7.5 x IO-” M 
unlabcllcd a-Bgt, [rz51]a-Bgt binding in the preecnce of 1 mM nicotine 
and of 25 mM acctylcholinel0.25 mM ncoostigminc was also measured 
for additional controls. 
2.4. Pcpride swutwsis 
Solid phase synthais was ~~rricc! out with a model 430A automatic 
synthesizer (Applied Biosystems. Foster City. CA) employing Fmmoc 
chemistry. The pcptide scqucnce was checked by a pas.phasc microsc- 
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qucnccr (Model 470A. Applied Biosystcm). HGl65-178 was conju- 
gated with KLH by glutaraldehydc, about 300 mol of puptidc were 
bound per mol of KLH. The conjugated pcptide (cHG) was used for 
inhibition experimcms and for immunization of mice. 
5 x IO5 cells in 100 /rl of PBS wcrc incubated with 50 yl of serial 
dilutions of peptides for 2 h. [‘ZJI]a-Bgt ( IO’cpm) were lhcn addcd and 
incubated for 45 min, The cells werewashed and radioactivity counted 
as described above. iMaximum binding was detcrminod by replacing 
inhibitors with as?;oy buffer. KLH and an uncorrelnted I4-amino acid 
peptidc onjugated to KLH (SI) were used under the SBrnc ondhions 
to check non-specific inhibition. 
2.6. htihodics 
Balb/c mice were injected intrapetitoncally with 250 /QJ of HG 165. 
I78 KLH-conjugated peptidc in complete Freund’s adjuvant (CFA) 
(day I). The mice were boosted as above using incomplete Freund’s 
adjuvant at days I5 and 36. At day 57, the mice were injected intmve- 
nously with 100 yg conjugate in saline. After 3 clays serum from 
immunized animals was collected for the experiments (polyclonal an- 
tibodies). 
2.7. ELISA 
Anti-HGl65-I78 mouse antiserum was tested cm three dilT’ercnt 
antigens. 96-well EIA plates were coated with HIV-l gpl20. RV 
glycoprotein or a-Bgt in 50 mM ammonium carbonate buffer. pi-i 9.5, 
for Ii3 h at 4°C. The plates were then washed and quenched with 3% 
bovine strum albumin, washed again and incubated with serial dilu- 
tions of antiserum for 3 h at 37°C Binding was dctcctcd by horse- 
radish peroxidase-conjugated anti-=?use IgG. 
3. RESULTS AND DISCUSSION 
A significant homology is present between the se- 
quence, 164-174, of HIV-I gp120 and the active sites 
responsible for the binding of snake neurotoxins and 
rabies virus glycoprotein to muscle AChR (Fig. 1). 
The human rhabdomyosarcoma cell line, TE671. is 
known to express a muscle-like nicotinic receptor [B]. 
[“‘I]a-Bgt binding to the nicotinic receptor in the 
TE671 cell line was measured on intact cells. Non-spe- 
cific binding was checked in the presence of a high 
excess of unlabclled a-Bgt. No binding of [l”Sl]a-Bgt 
was detected on hepatoma PLC/PRF/S (data not 
shown), a different human cell line. Gp120 from the 
HIV-1 strain IIIB was found to inhibit the binding of 
a-B@ to TE671: 30% of maximum binding (B,) was 
measured in the presence of 2 x lo-’ M gp120 (Fig. 2). 
Acetylcholinc and nicotine were used under the same 
condirions to specifically inhibit the binding, as already 
described for a-B@ binding to torpedo AChR [7,9]. 
HIV-l gp120 inhibition of a-Bgt binding indicates a 
‘functional equivalence’ between these proteins for nico- 
C-D-I-F-T-N-S-R-G-K-R RY glycoprolcin (residues 189-199) 
F-N-I-S-T-S-I-R-Z-K-V HIV.1 gp12.0 [residues 164-174) 
C-D-A-FX-S-I-R-G-K-R a-cobrtuoxin (residues 30-40) 
C-C-A-FC-S-S-R-G-K-V a-biingarotoxin (rcsiducs 30-40) 
Fig. I I Sequcncc homology of HlY-I gpl20 with rabies virus glycopro- 
tein and snake venom ncurotoxins. 
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Fig. 2. [lZ’l]a-Bgt binding to TE67 I AChR in the presence of (ACh) 
2.5 x IO-? M acetylcholhW2.5 x IOmJ M ncostigminc; (Nit) IO-” M 
nicotine:(l)2x IO-‘Mgpl20:(2) IO-‘Mgpl20:(3)5x IO-” Mgpl20: 
(4) 2.5 x IO-’ M gpl20. Each point is the mean of duplicate detcrmi- 
nations after subtraction of non-spccilically bound radioactivity (B), 
(&). Maximum binding (see text). 
tinic receptor binding. To investigate whether the se- 
quence of HIV-1 gp120, homologous to snake neuro- 
toxins and rabies virus glycoprotein, might be involved 
in the binding of gpl20 to AChR, we synthesized a
14-amino acid peptide (HG165-78: Asn-Ile-Ser-Thr- 
Ser-Ile-Arg-Gly-Lys-Val-Gin-Lys-Glu-Tyr), reproduc- 
ing the sequence 165-178 of gpl20. Once conjugated to 
KLH this peptide inhibits [‘zSl]a-Bgt binding to intact 
TE671 cells (Fig. 3). About 40% of maximum binding 
was obtained in the presence of 1.4x lo-’ M conjugated 
peptide, but we could not measure any significant inhi- 
bition with the free peptide. 
The effect of the protein carrier is not surprising. It 
has been reported in other cases and attributed to the 
stabilization of the peptide active conformation [lo]. In 
our case the further ability of gp120 to inhibit the bind- 
ing of a-&t to the nicotinic receptor in TE671 seems to 
indicate that the HG165-178 active conformation is 
similar to the one this sequence assumes in the native 
protein. Moreover immunization of mice with KLH- 
conjugated HG 165- 178 gave rise to an antiserum which 
bound to gpl20 and also recognized rabies virus 
glycoprotein and a-Bgt in ELISA (Fig. 4), confirming 
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Fig. 3. [“‘I]~-Bgt binding to TE67I AChR in the presence ofdilTercnt 
concentrations of the following competing ligands: KLH-conjugated 
HG165-17s (cHG), KLH, and an uncorrclated 14-amino acid KLH- 
conjugated peptidc (SI). 
the possibility of a structural similarity between the re- 
gions of these proteins having remarkable sequence ho- 
mology. In the light of our results we cannot exclude the 
possibility that inhibition of a-B@ binding to TE671 
cells by HIV-I gpl20 is due, at least in part, to receptor 
down-regulation following gpl20 binding. 
The existence of an HIV-l receptor alternative to 
CD4 in neurones and muscle cells is strongly suggested 
by evidence of the ability of HIV-I to infect CD4-nega- 
tive muscle and neural cells [ 11,121 and the lack of inhi- 
bition by soluble CD4 of HIV-l infection of muscle and 
neuronal cell lines [13]. Galactosyl ceramide has been 
reported to specifically bind HIV-1 gp120, and has been 
proposed as an essential component of HIV-l receptors 
in neural cell lines and brain cells expressing this or a 
related lipid [14,153. Our evidence of the binding of 
gp120 to TE671 nicotinic receptors helps to explain 
HIV-l infection of muscle cell lines, and suggests that 
nicotinic receptors may also bind HIV-l gpl20 in neural 
cells. At least wo populations of nicotinic receptors are 
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Fig. 4. Anti.KLH*conjugaated HGltX-I78 mouse polyclonal antibod- 
ies tested in ELISA on RVG (+RVG), gpl20 (+gpl20) and &BSt 
(+Bgt), compared to equivalent dilution of normal mouse serum 
(-RVG). (-gpl20) and (-Bgt). 
expressed in the nervous system [16], one of which is 
labelled by a-Bgt. Moreover some of the cell lines, such 
as RD, TE671 and IMR32, in which a CD4-independ- 
ent infection by HIV-1 has been proposed, are known 
to express or-Bgt binding nicotinic receptors [8,17]. 
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